Ou Xiaojuan, Wang Xiaoming, Wu Xiaoning, Kong Yuanyuan, Duan Weijia, Zhou Jialing, Sun Dongyang, Wang Yu, You Hong, Jia Jidong
LiverResearch Center, Beijing FriendshiPHospital, Capital Medical University, Beijing 100050, China.
Zhonghua Gan Zang Bing Za Zhi. 2015 Feb;23(2):103-6. doi: 10.3760/cma.j.issn.1007-3418.2015.02.006.
To perform a comparative assessment of the performance of FibroTouch and FibroScan in patients with hepatitis B.
A total of 211 patients with hepatitis B, including cases of chronic hepatitis B (CHB) and of compensated cirrhosis, were enrolled for study between June and November of 2013. The patients underwent FibroScan testing (group 1) and FibroTouch testing (group 3), after which the operator examined a time motion ultrasound image from the FibroScan test and located a specific liver portion for focused FibroTouch testing (group 2). The consistency between the two tests' results was investigated by Pearson's correlation analysis, and the difference of liver stiffness between CHB patients and compensated cirrhosis patients was investigated by the two independent samples t-test or Mann-Whitney U test.
The values of liver stiffness were 5.30 (4.30,8.65) in group 1,6.10 (4.70,8.90) in group 2, and 5.70 (4.50, 8.00) in group 3 (all P < 0.05); the Pearson correlation coefficients were all more than 0.8 (P < 0.05) and there was no statistically significant difference found between the results from FibroScan and FibroTouch.The values of liver stiffness were significantly different between the CHB patients and the compensated cirrhosis patients (P < 0.05). The rates of successful detection were 100% for FibroTouch and 97% for FibroScan.
FibroTouch and FibroScan have good consistency in the evaluation of the degree of liver fibrosis. FibroTouch has a higher rate of successful detection than FibroScan.
对FibroTouch和FibroScan在乙型肝炎患者中的性能进行比较评估。
2013年6月至11月共纳入211例乙型肝炎患者，包括慢性乙型肝炎（CHB）和代偿期肝硬化患者。患者接受FibroScan检测（第1组）和FibroTouch检测（第3组），之后操作人员检查FibroScan检测的时间-运动超声图像，并定位特定肝脏部位进行FibroTouch聚焦检测（第2组）。通过Pearson相关分析研究两种检测结果之间的一致性，通过两独立样本t检验或Mann-Whitney U检验研究CHB患者和代偿期肝硬化患者之间肝硬度的差异。
第1组肝硬度值为5.30（4.30，8.65），第2组为6.10（4.70，8.90），第3组为5.70（4.50，8.00）（均P<0.05）；Pearson相关系数均大于0.8（P<0.05），FibroScan和FibroTouch的结果之间无统计学显著差异。CHB患者和代偿期肝硬化患者的肝硬度值有显著差异（P<0.05）。FibroTouch的成功检测率为100%，FibroScan为97%。
FibroTouch和FibroScan在评估肝纤维化程度方面具有良好的一致性。FibroTouch的成功检测率高于FibroScan。
